Menu
Minicircle has completed a Phase I clinical trial on a follistatin gene therapy that may be able to treat or delay the onset of aging. This gene therapy produced extraordinary reductions in epigenetic clock age (biological measurements of age) and improvements in tissue composition.
Discovered in 1997, mice lacking the klotho gene age quickly and die young, but mice overexpressing klotho live 30% longer than their peers. Further research has shown that klotho overexpression improves cognition and cardiometabolic health.
Klotho has been shown in preclinical studies to improve kidney, lung, pancreas, and brain function, and to act as a universal tumor suppressor. Klotho primarily binds to and activates FGF23, but it promotes healthy longevity via numerous mechanisms including but not limited to antioxidant defense.
Klotho is widely recognized to have potential in slowing or reversing age-related cognitive decline, chronic kidney disease, and pancreatic cancer.
Our Phase I follistatin gene therapy investigated bone density, lean body mass, body fat distribution, cholesterol balance, glycemic response, epigenetic clock age, telomere length, and markers of inflammation.
Follistatin is a morphogenetic hormone which improves tissue composition and extends lifespan in healthy mice by 32.5%. It has marked effects improving the felt sense of well-being and has been shown in early human studies to increase bone density and muscle mass, decrease bodyfat, and to reduce the epigenetic clock age (“biological age”).
Follistatin is widely cited as a good candidate for an investigational therapy of sarcopenia, ALS, and FSHMD. Learn more in our preprint here.
Plasmids are the future of medicine. Plasmids are small circular loops of DNA that are completely non-inflammatory, easy to manufacture and distribute, do not integrate into or edit your original chromosome, are not heritable, and can be designed to include responsive switches allowing the gene to be turned on or off via the consumption of an activator pill.
We have designed these plasmids as a friendly and safe universal platform for reversible gene therapy.
Plasmid therapy promises unlimited health, independence from disease, and to reimagine the future of our identity.
Clinical Development - Phase I
Follistatin is a morphogenetic protein with a broad range of effects including the capacity to inhibit myostatin in a tissue specific manner. Follistatin is a candidate for multiple therapeutic modalities.
Discovery & Preclinical Development - Candidate
Testosterone is a master regulator hormone controlling self-confidence, risk-taking behavior, emotional stability, body composition, rational thinking, cognitive well-being, and libido. Low testosterone levels are endemic in modern civilization where sedentary lifestyles are common and industrial hyperestrogenic compounds are constantly consumed in air, water, and food.
Discovery & Preclinical Development - Candidate
Discovery & Preclinical Development - Candidate
Clinical Development - Phase I
Our innovative HIV plasmid therapy constantly delivers human origin broadly neutralizing antibodies discovered by the US National Institutes of Health. This therapy is designed to be distributed in high temperature climates like Africa, India, and Central America and does not require refrigeration. Our hope is that this therapy can be proven both as a “functional cure” for HIV as well as a safe and effective prophylactic designed for global eradication of HIV.
Discovery & Preclinical Development - Lead
Our herpes gene therapy will work similarly to our HIV gene therapy. Broadly neutralizing antibodies that bind to HSV 1 & 2 can be constantly produced and secreted into the bloodstream in hopes of eliminating the transmission and symptoms of HSV.
Discovery & Preclinical Development - Candidate
Our innovative therapy for Crohn’s disease uses plasmids to deliver TNF-alpha neutralizing antibodies at a constant rate for 1-2 years. This therapy, if successful should be able to replace the functionality of existing biologics.
Discovery & Preclinical Development - Candidate
A combination of antibodies and morphogenetic proteins can be delivered to create an expected 25% decrease in body fat with a single injection.
Discovery & Preclinical Development - Candidate
Discovery & Preclinical Development - Lead
Discovery & Preclinical Development - Lead
Discovery & Preclinical Development - Candidate
Copyright © 2024, Minicircle.